BREAKOUT STOCK ALERT UPDATE
OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM)
Initial Alert Price: $1.32
Price High: $1.65
% Gains/Losses: 25%
(+5.3% More Than Expected)
Potential Stop Loss: $1.5675
OTLK bounced back to the $1.65 Price Level into Today's Trading Session before meeting resistance and consolidating back the $1.42 to find additional support at those levels. The stock is actually sitting right at our Price Target around the $1.58 providing our 30% Target Gains from the initial trade alert, but after finding support around the $1.40 Levels of Resistance, we could see the stock continuing to trade within the $1.40 - $1.78 over the new few trading session to again retest those $1.73 Levels of Resistance.
This comes after the Director GM Ventures & Investments reported purchasing 8.36M Shares at $1.00/Share in Form 4 Filings on Tuesday. The next price ranges beyond those $1.73 Price Levels would be between the $1.73 - $2.89 Price Ranges #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
Initial Alert Price: $1.32
Price High: $1.65
% Gains/Losses: 25%
(+5.3% More Than Expected)
Potential Stop Loss: $1.5675
OTLK bounced back to the $1.65 Price Level into Today's Trading Session before meeting resistance and consolidating back the $1.42 to find additional support at those levels. The stock is actually sitting right at our Price Target around the $1.58 providing our 30% Target Gains from the initial trade alert, but after finding support around the $1.40 Levels of Resistance, we could see the stock continuing to trade within the $1.40 - $1.78 over the new few trading session to again retest those $1.73 Levels of Resistance.
This comes after the Director GM Ventures & Investments reported purchasing 8.36M Shares at $1.00/Share in Form 4 Filings on Tuesday. The next price ranges beyond those $1.73 Price Levels would be between the $1.73 - $2.89 Price Ranges #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.